GLPG.AS
Latest Trade
146.70EURChange
1.45(+1.00%)Volume
145,245Today's Range
-
146.7052 Week Range
-
171.20As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 145.25 |
|---|---|
Open | 144.90 |
Volume | 145,245 |
3M AVG Volume | 8.86 |
Today's High | 146.70 |
Today's Low | 144.35 |
52 Week High | 171.20 |
52 Week Low | 74.48 |
Shares Out (MIL) | 54.82 |
Market Cap (MIL) | 8,954.97 |
Forward P/E | -32.21 |
Dividend (Yield %) | -- |
Pharnext Updates On Collaboration with Galapagos
Galapagos Files Application To Initiate Insolvency Proceedings
BRIEF-Galapagos Files Application To Initiate Insolvency Proceedings
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
Industry
Biotechnology & Drugs
Executive Leadership
Onno van de Stolpe
Chairman of the Executive Committee, Chief Executive Officer, Executive Director
Rajesh B. Parekh
Non-Executive Chairman of the Board
Bart Filius
Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer
Piet Wigerinck
Member of the Executive Committee, Chief Scientific Officer
Walid Abi-Saab
Member of the Executive Committee, Chief Medical Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 27.60 |
Price To Book (MRQ) | 6.96 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 2.24 |
LT Debt To Equity (MRQ) | 1.79 |
Return on Investment (TTM) | -6.22 |
Return on Equity (TTM) | -5.16 |
* ANNOUNCED ON THURSDAY AN ISSUE OF 301,745 NEW ORDINARY SHARES ON SEP 18, 2019, FOR TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 6.7 MLN
* GALAPAGOS-FILED APPLICATION TO INITIATE INSOLVENCY PROCEEDINGS WITH COMPETENT LOCAL COURT OF DÜSSELDORF DUE TO PENDING ILLIQUIDITY & OVER-INDEBTEDNESS
U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>, news that lifted Galapagos's shares more than 18% to an all-time high on Monday.
U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>.
Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm's treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.
* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Shares in Belgian drugmaker Galapagos surged nearly 16 percent on Friday after the company said it had seen positive results from several safety and efficacy trials of its rheumatoid arthritis drug filgotinib.
* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES
* SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO
* SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS
Rheinmetall <RHMG.DE> on Monday said it was in talks about buying a stake in rival KMW and Nexter Defense Systems N.V, sending shares in the defense company sharply higher.
* ANNOUNCED ON FRIDAY A SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES
* REPORTED ON WEDNESDAY TOPLINE INTERIM RESULTS OF FALCON TRIAL PART 1 IN CF
* REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION
* REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS
* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES
Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.
Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.
* CASH AND CASH EQUIVALENTS ON 30 JUNE 2018 OF €1,066.8 MILLION
Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.